



May 22, 2020

Treatment of coagulopathy in COVID-19 patients: protocol for a scoping review

 International Journal of Hematology

DOI

dx.doi.org/10.17504/protocols.io.bgrpjv5n

Hiroataka Mori¹, Hiroshi Ohkawara¹, Takayuki Ikezoe¹, Ryuichi Togawa², Mami Rikimaru², Yoko Shibata²

¹Department of Hematology, Fukushima Medical University, Fukushima 960-1295, Japan;

²Department of Respiratory Medicine, Fukushima Medical University, Fukushima 960-1295, Japan



Hiroataka Mori

Department of Hematology, Fukushima Medical University, Fuku...

Create & collaborate more with a free account

Edit and publish protocols, collaborate in communities, share insights through comments, and track progress with run records.

Create free account

OPEN  ACCESS



DOI: <https://dx.doi.org/10.17504/protocols.io.bgrpjv5n>

External link: <https://doi.org/10.1007/s12185-021-03084-z>

Protocol Citation: Hiroataka Mori, Hiroshi Ohkawara, Takayuki Ikezoe, Ryuichi Togawa, Mami Rikimaru, Yoko Shibata 2020.

Treatment of coagulopathy in COVID-19 patients: protocol for a scoping review. **protocols.io**

<https://dx.doi.org/10.17504/protocols.io.bgrpjv5n>

Manuscript citation:

Mori H, Ohkawara H, Togawa R, Rikimaru M, Shibata Y, Ikezoe T, Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. International Journal of Hematology doi: [10.1007/s12185-021-03084-z](https://doi.org/10.1007/s12185-021-03084-z)

License: This is an open access protocol distributed under the terms of the **[Creative Commons Attribution License](#)**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

We use this protocol and it's working

Created: May 22, 2020

Last Modified: May 22, 2020

Protocol Integer ID: 37391

Keywords: COVID-19, coagulopathy, anticoagulant, scoping review, scoping review background coronavirus infection disease, review background coronavirus infection disease, evidence of anticoagulant, intravascular coagulation, scoping review methodology, preferred reporting items for systematic review, systematic review, scoping review protocol, review of available evidence, investigated treatment,

Abstract

Background

Coronavirus infection disease 2019 (COVID-19) patients have a significant association with coagulopathy and disseminated intravascular coagulation contributing to high mortality. The treatment of COVID-19 and the control of coagulopathy are the primary concern. Although the evidence of anticoagulants in COVID-19 patients with coagulopathy is compiling, there is no scoping review to systematically map the anticoagulants used in this area and to identify the existing gaps between investigated treatment and not. The objective is to conduct a scoping review of available evidence on the anticoagulants in COVID-19 patients with coagulopathy.

Methods

For conducting the scoping review protocol, we will use a scoping review methodology in the Joanna Briggs Institute manual. This methodology has a five-stage approach:

(1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data and (5) collating, summarize and report the results. We also will use the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews to assess the results.

Ethics and dissemination

Because this is a review of the literature, ethics approval is not indicated. We will disseminate the findings from this review in publications in peer-reviewed journals.

Attachments



[protocol.pdf](#)

663KB

Troubleshooting

